Meet us at DIA’s Medical Information and Communications Conference in Barcelona, Spain
Meet us at DIA’s Medical Information and Communications Conference in Barcelona, Spain Universal Medica’s medical information team is looking forward to participating in DIA’s Medical Information and Communications Conference, which is taking place October 5th-6th in Barcelona, Spain. The event is organized by medical information professionals for medical information professionals to explore key medical information […]
Meet us at World Drug Safety Congress Europe
Universal Medica’s pharmacovigilance team is looking forward to participating in this year’s World Drug Safety Congress Europe, which will be held from September 27-29 at the RAI Congress Centre in Amsterdam. The World Drug Safety Congress is expected to bring together 700+ key opinion leaders from the life science industry to explore and discuss the challenges […]
Revision of Good PharmacoVigilance Practices in France
We are pleased to share our summary of the revision of the Good Practices of PharmacoVigilance in France: although this revision does not bring major changes to the national system, it adds clarifications on the processes in place as well as an update of the description of the processes that have evolved since the previous […]
Universal Medica Group acquires Zebra Santé
UNIVERSAL MEDICA Group has taken a new step in its development with the acquisition of ZEBRA Santé, an expert in pharmacist communication. This acquisition is part of the group’s «Horizon 2025» strategic plan and meets the needs of the transforming healthcare sector. Through this acquisition, UNIVERSAL MEDICA Group offers a real synergy of activities to […]
How to qualify for orphan designation in the European Union?
There are more than 7000 rare diseases affecting over 400 million people worldwide and 30 million people in European Union. However, only about 5% of rare diseases currently have approved treatments. As many of these diseases are life-threatening, there is a serious need to develop new drugs for rare diseases. Historically, drug development for rare […]
Universal Medica Gender Equality index for the year 2021
In compliance with the provisions of Avenir law (5 September 2018) on freedom of choice in professional career places, Universal Medica publishes its gender equality index for the year 2021. This law aims to eliminate the pay gap between women and men in France. In 2021, Universal Medica’s gender equality score increased to 95 from […]
How to obtain the EMA’s Single Marketing Authorization?
All human medicines derived from biotechnology and other high-tech methods must be evaluated by the European Medicines Agency (EMA) via the centralized procedure called single marketing authorization before they can be marketed and made available to patients in the EU. The evaluation process is carried out by the EMA’s Committee for Medicinal Products for Human Use (CHMP) with […]
Seamless And Holistic Business Continuity Approach To Ensure Patient Safety And Well-Being Throughout The Year
2021 was a year of new possibilities and opportunities. Together we showed unity, adaptability and exceptional willingness to emerge stronger from the COVID-19 pandemic. As the end of 2021 draws closer, it is important to continuously chart a path that empowers everyone to face the future with confidence and build a resilient recovery. At Universal Medica Group we kept going […]
Universal Medica Group 5 poles of expertise
Webinar – 7 key points for a successful pharmacovigilance inspection
Language – French The pharmacovigilance inspection is one of the most important practice in terms of workload (preparation, implementation of action plans, etc.) and/or in terms of image (in the event of an injunction, for example). During a PV inspection, the pharmacovigilance system, and the involvement of all those stakeholders are scrutinized. This webinar aims […]
